Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Parameswaran Hari MD
Chief, Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
10/1985 - 06/1992 MB/BS, Uni, University of Kerala, India
06/1992 - 03/1995 MD, Central University of Pondicherry, Pondicherry, India
09/2004 - 05/2006 MS, Medical College of Wisconsin, Milwaukee, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
06/1992 - 04/1995 Resident, Internal Medicine, Jawaharlal Institute of Post-Graduate Medicine & Research, India
04/1996 - 02/1997 Oxford Postgraduate, Senior House Officer in Medicine, Deanery, UK
02/1997 - 08/1997 Manchester Postgraduate, Senior House Officer in Hematology, Deanery, UK
08/1997 - 06/2000 Trent Post Graduate, Specialist Registrar in Hematology, Deanery, UK
07/2000 - 06/2002 Resident, Internal Medicine, Jefferson Health, Lankenau Hospital, Philadelphi, PA
07/2002 - 06/2004 Fellowship, Oncology, Medical College of Wisconsin, Milwaukee, WI

FACULTY APPOINTMENTS:
06/2004 - 03/2009 Assistant Professor, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
04/2009 - Present Associate Professor, Department of Medicine, Division of Neoplastic Diseases and Related Disorders

ADMINISTRATIVE APPOINTMENTS:
02/2007 - Present Clinical Director, Adult Blood and Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI

RESEARCH ADMINISTRATIVE APPOINTMENTS:
07/2004 - Present Asst. Scientific Director, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226

HOSPITAL STAFF PRIVILEGES:
07/2004 - Present Froedtert Memorial Lutheran Hospital, 9200 W. Wisconsin Ave., Milwaukee, WI 53226

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Royal College of Physicians Internal Medicine
02/1997
None
Royal College of Pathologists Clinical & Laboratory Hematology
12/1999
None
 
Certificates
Issued By Issue DateExpiration
Transfusion Medicine
National Blood Service, UK
03/1999
None
Coagulation Medicine
WHO Coag Labs. Manchester, UK
10/1999
None
American Board of Internal Medicine
10/2002
10/2010
ABIM - Oncology
10/2004
10/2014
 

Licensure
Number Issue DateExpiration
Indian Medical Council (New Delhi, India)
06/1992
None
General Medical Council (London, UK)
12/1995
None
Wisconsin License
07/01/2002
10/31/2009
 

AWARDS AND HONORS:
06/2002 Best Teaching Resident Award, Jefferson Health, Lankenau Hospital, PA
06/2007 Best Doctors in America
06/2008 Dennis Bush Award for Teaching Excellence, Division of Neoplastic Diseases

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
02/1997 - Present Royal College of Physicians, Edinburgh, UK (Member)
12/1999 - Present Royal College of Pathologists, London, UK (Member)
06/2003 - Present American Society of Hematology (Member)
Wisconsin Myeloma Support Group (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
Bone Marrow Transplantation
Leukemia Lymphoma
American Journal of Hematology
Faculty of Medicine 1000
Blood
Mayo Clinic Proceedings
Journal of Palliative Care

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
07/2005 - Present Member, Patient Services Committee, Leukemia Lymphoma Society
09/2007 - Present Member, Institutional Review Board, Medical College of Wisconsin

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
06/2004 - Present Scientific Director, Plasma Cell Disorders Working Committee, CIBMTR
06/2004 - Present Scientific Director, Lymphoma Disorders Working Committee, CIBMTR
10/2007 - Present Member, Myeloma Clinical Trials Working Group, Bone Marrow Transplant Clinical Trials Network (BMT- CTN)
02/2008 - Present Member, Core Committee, Bone Marrow Transplant Clinical Trials Network (BMT- CTN)
04/2008 - Present Member, Reimbursement Committee, Bone Marrow Transplant Clinical Trials Network
Member, Patient Services Committee, Leukemia, Lymphoma Society

INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
01/01/2013 - 12/31/2014 Governing Board, Association of Physicians of Indian Origin
08/14/2013 - 08/14/2014 President, Association of Kerala Medical Graduates

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Ex-vivo Cultured Adult Human Mesenchymal Stem Cell Infusion for the Treatment of Steriod-Refractory Acute GVHD
Source:
Quintiles – 280
Role:
Principal Investigator
PI:
Self
Dates:
12/22/2006 - 09/30/2014
Direct Funds:
$77,065
 
Title:
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal
Source:
Osiris Therapeutics, Inc. - 265
Role:
Principal Investigator
PI:
Self
Dates:
09/14/2007 - 02/15/2014
Direct Funds:
$14,994
 
Title:
An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma
Source:
Dana-Farber/Partners Cancer Care, Inc (Celgene/Novartis) – 07-2
Role:
Principal Investigator
PI:
Self
Dates:
02/24/2009 - 02/23/2012
Direct Funds:
$6,000
 
Title:
Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma
Source:
CIBMTR/NMDP – 07-REV
Role:
Principal Investigator
PI:
Self
Dates:
06/09/2009 - 06/08/2012
Direct Funds:
$4,250
 
Title:
Phase ib Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma
Source:
Onyx Pharmaceuticals – PX-171-006
Dates:
01/05/2010 - 01/04/2013
Direct Funds:
$13,130
 
Title:
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients with Relapsed Muliple Myeloma
Source:
Cephalon – C18770-2043
Dates:
03/16/2010 - 03/15/2013
Direct Funds:
$18,632
 
Title:
Vascular dysfunction and oxidative stress in primary amyloidosis
Source:
NIH
Role:
Co - Principal Investigator
 
Title:
Endothelial Dysfunction in Adipose Arterioles Exposed to AL Amyloid Light Chains and the Effect of Simvastatin Treatment
Source:
American Cancer Society
Role:
Co - Principal Investigator
Direct Funds:
$30,000
 
Non-Peer Review
Title:
A Data Resource for Analyzing Blood and Marrow Transplants
Source:
NIH/NCI – U24 CA 76518-11
Dates:
05/15/2003 - 02/28/2013
Direct Funds:
$2,552,159
 
Title:
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Comparing Three Doses of Tanespimycin in Patients with Relapsed-Refractory Multiple Myeloma
Source:
KOSAN BIOSCIENCES INCORPORATED
Role:
Principal Investigator
PI:
Self
Dates:
07/31/2008 - Present
 
Pending
Peer Review
Title:
Phase II/III Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation Cyclophosphamide ATGAM & Autologous Transplantation with Audo-CD34+HPC vs. Intravenouse Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis
Source:
Duke University Medical Center – N01 AI 05419
Role:
Principal Investigator
PI:
Self
Dates:
03/03/2005 - 09/21/2012
 
Prior
Peer Review
Title:
A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination w/Bortezomib Compared with Bortezomib in Pts w/Relapsed or Refractory Multiple Myeloma
Source:
Genentech - AVF4064g
Role:
Principal Investigator
PI:
Self
Dates:
01/05/2007 - 10/21/2010
Direct Funds:
$5,400 ($13,391/patient cost)
 
Title:
A Phase 2 Randomized study of Velcade (Bortezomib), Dexamethasone, and Revlimid (Lenalidomide) (VDR) versus VELCADE, Dexamethasone, Cyclophosphamide and Revlimid (VDCR) in Previously Untreated Patients with Newly Diagnosed Symptomatic Multiple Myeloma
Source:
Millennium – C05008
Role:
Principal Investigator
PI:
Self
Dates:
07/02/2007 - 06/01/2010
Direct Funds:
$5,400 ($8,685/patient cost)
 
Title:
Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus bortezomib Compared to Bortezomib Alone in Patients with Multiple Myelomas in First Relapse
Source:
Bristol Myers Squibb Company – KAG-301
Dates:
07/30/2008 - 07/29/2010
Direct Funds:
$41,023
 
Title:
An Internatonal, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
Source:
Covance – 095
Dates:
10/28/2008 - 04/27/2010
Direct Funds:
$15,951
 
Non-Peer Review
Title:
A Single Arm, Multicenter Phase II Trial of Transplants of HLA-Matched, CD34+ Enriched, T cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients with AML in First or Second Morphologic Complete Remission BMT CTN Protocol #0303
Source:
National Marrow Donor Program - 0303
Role:
Principal Investigator
PI:
Self
Dates:
01/01/2005 - 04/30/2011
Direct Funds:
$10,479
 
Title:
Prevention of Osteoporosis in Survivors of Allogeneic Bone Marrow Transplantation
Source:
University of Minnesota/Novartis Pharmaceuticals - 20082919
Role:
Principal Investigator
PI:
Self
Dates:
08/01/2005 - 06/30/2011
Direct Funds:
$5,355
 
Title:
A Phase II Randomized Double Blind Placebo Controlled Trail to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant
Source:
CuraGen Corporation – CG53135-CLN-12
Role:
Principal Investigators
PI:
Self
Dates:
03/07/2006 - 10/06/2008
Direct Funds:
$1,875
 
Title:
A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients >60 Years Old with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens
Source:
Genzyme – CL034100405
Role:
Principal Investigator
PI:
Self
Dates:
12/19/2006 - 12/31/2010
Direct Funds:
$17,543
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Novel Agents in Plasma Cell Disorders, SWOPS Pharmacology Meeting, Minneapolis, MN, 03/2005
Research in Myeloma, Leukemia Lymphoma Society Talk, 09/2005
Transplantation in Myeloma, Wisconsin Myeloma Patient and Caregiver Annual Forum, 11/2005
Free Light Chains in Myeloma – Boon or Bane?, CME Program, Milwaukee, WI, 06/2006
What is New in Myeloma?, CME Program, Racine Oncology, Racine, WI, 06/2006
Clinical Trials in Medicine – What is in it for the Patient?, Leukemia Lymphoma Society Talk, 09/2006
Basic Facts in Myeloma, Wisconsin Myeloma Patient and Caregiver Annual Forum, 11/2006
Updates from ASH 2006 – Myeloma & Amyloid, CME Program, Appleton, WI, 02/2007
CML – What is new?, Leukemia Lymphoma Society Talk, 02/2007
Basics of Myeloma, Wisconsin Myeloma Patient and Caregiver Annual Forum, 09/2007
Plasma Cell Disorders in Primary Care, Wisconsin Primary Care Meeting, Door County, 10/2007
Plasma Cell Disorders and Transplantation, ASH update, Medical College of Wisconsin, 01/2008
Multiple Myeloma – What is new?, Joliet Oncology, CME conference & ASH update, 02/21/2008
Multiple Myeloma – Translating the evidence into practice, SWOPS Conference, Milwaukee, WI, 06/2008
Transplantation in Myeloma, Wisconsin Myeloma Patient and Caregiver Annual Forum, 10/2008
New treatments in Myeloma, International Myeloma Foundation, Patient and caregiver conference, 06/2009
Newly diagnosed Myeloma – what you need to know and what you need to ask?, Wisconsin Myeloma Patient and Caregiver Annual Forum, 09/2009
Mobilization of Hematopoietic Stem Cells, SWOPS Conference, Milwaukee, WI, 04/2010
 
Regional
Cell Processing for Hematopoietic Stem Cell Transplants, National Marrow Donor Program Council Meetings, Minneapolis, MN, 10/2005
Autologous and Allogeneic Transplantation for Plasma Cell Disorders, Grand Rounds, Rush St Luke Presbyterian Medical Center, Chicago, IL, 03/2006
Plasma Cell Disorders, National Marrow Donor Program Council Meetings, Minneapolis, MN, 10/2006
Novel Drugs in Acute Myeloid Leukemia, United Health Networks National Meeting, Minneapolis, MN, 10/2007
Multiple Myeloma Update, Gross Pointe Oncology, MI, 11/28/2007
 
National
Data Management in Myeloma, Tandem BMT Meetings, Keystone, CO, 02/2005
Response, relapse and Remission – How to decide, how to report, Tandem BMT Meetings, Honolulu, HI, 02/2006
Data Management in Myeloma, Tandem BMT Meetings, Keystone, CO, 02/2007
Debate in Myeloma – Cure vs. Control, Celgene Annual Forum, San Diego, CA, 10/2009
The Free Light Chain test – uses and pitfalls, Freelite Webinar, 03/2010
 
International
State of the Art in Hematopoietic Stem Cell Transplantation, National Consensus Conference on Cancer Guidelines, Jaipur, India, 10/23/2005
Warwick Conference on the use of Free Light Chains in Myeloma, University of Warwick, UK, 09/28/2006
AL Amyloidosis – To transplant or not?, Brazilian Society of Blood and Marrow Transplantation (SBTMO) Annual Meeting, 08/2009
AL Amyloidosis – To transplant or not?, Brazilian Society of Blood and Marrow Transplantation (SBTMO) Annual Meeting, 08/2009
Uses and Benefits of Large databases, Golden Jubilee Meeting Indian Society of Hematology and Transfusion Medicine, 11/2009
Reduced Intensity, Nonmyeloablative and Mini Transplant. What is in a name?, American Society of Oncology Annual Meeting, 06/2010
Reduced Intensity Transplantation for Lymphoma, Golden Jubilee Meeting Indian Society of Hematology and Transfusion Medicine
 

COMMITTEE SERVICE:
Medical College
07/2004 - Present Member, Fellowship Committee, Division of Neoplastic Diseases, Medical College of Wisconsin
07/2005 - Present Member, Residency Selection Committee, Department of Medicine, Medical College of Wisconsin
07/2007 - Present Member, Institutional Review Board #1, Medical College of Wisconsin
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Clinical/Research Fellows
Dan Vogl, MD, University of Pennsylvania, Dr. Vogl’s Master’s Thesis Research Project entitled “ Role of Dosing Body Weight in Autotransplantation in Myeloma”
Anuj Mahindra, MD, Cleveland Clinic, Mentored Dr. Mahindra’s research project through the CIBMTR “Hemtopoietic Cell Transplantation for Plasma Cell Leukemia”
 

TEACHING ACTIVITIES:
- Have mentored several IM residents in clinical research and have been extensively associated with residents in presentations and publications. - Residents have identified me as one of the key faculty under whose mentorship their fellow aspirations in hematology/oncology can be realized. - Key participant in the residents’ didactic teaching program. - Served on the residency selection committee for the past three years.
- Primarily responsible for curriculum development and coordination of training for the hematology oncology fellows in hematopoietic stem cell transplantation. - Member of the fellowship committee and am identified as a key faculty member contributing to the training and mentoring of fellows. - Have been identified by the fellows as one of two top ranked faculty members in their education during each of the past 6 academic semesters.
- Regular participant in preclinical lecture series. - Have delivered the Oncology 101 lecture (Basics of Medical Oncology) every year for the past 3 years. - As part of the ICE teaching program, have participated in clinical teaching of 6 M3 students per year for the past 3 years.


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, et al. Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell-Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303.Biol Blood Marrow Transplant. 2011 Feb 12.
2. Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cell myeloma. Br J Haematol. 2011 Jan 3
3. Reece DE, Vesole DH, Shrestha S And Hari PN.Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. Clin Lymphoma Myeloma Leuk. 2010 Dec 1;10(6):458-63
4. Shidham VB, Hunt B, Jardeh SS, Barboi AC, Devata S, Hari P.Performing and processing FNA of anterior fat pad for amyloid. J Vis Exp. 2010 Oct 30;(44). pii: 174
5. Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P. Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. Br J Haematol. 2010 Apr 28. (epub ahead of print)
6. Hari PN, Majhail NS, Zhang MJ, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010 Mar;16(3):395-402
7. Migrino RQ, Mareedu RK, Eastwood D, Bowers M, Harmann L, Hari P. Left ventricular Ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr. 2009 Dec:22(12):1396-402. Epub 2009 Oct 31.
8. Harrington AM, Hari P, Kroft SH. Utility of CD56 immunohistochemical studies in follow-Up of plasma cell myeloma. Am J Clin Pathol. 2009 Jul;132(1):60-6.
9. Fenske TS, Hari PN, Carreras J,Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pretransplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov;15(11):1455-64.
10. Conway EJ, Wen J, Feng Y, Hari P, Vesole DH, Chang CC. Phenotyping studies of Clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry. Arch Pathol Lab Med. 2009 Oct;133(10):1594-9.
11. Migrino RQ, Hari P, Gutterman DD, et al. Systemic and microvascular oxidative stress Induced by light chain amyloidosis. Int J Cardiol. 2009 May 14.
12. Migrino RQ, Christenson R, Szabo A, Hari P. Prognostic implication of late gadolinium Enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. BMC Med Phys. 2009 May 5;9:5.
13. Hari P,Et al; Is The International Staging System Superior To the Durie Salmon Staging System? A Comparison In the Multiple Myeloma Patients Undergoing Autologous Transplant. Leukemia. 2009 Aug;23(8):1528-34.
14. Van Besien K, Carreras JC, Hari P; Unrelated donor Hematopoietic Cell Transplantation For NHL: Long term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63
15. Bashey A, Perez W, Hari P, Comparison of Twin and Autologous Transplants for Multiple Myeloma Biol Blood Marrow Transplant. 2008 Oct;14(10):1118-24.
16. Kumar S, Hari P, Comparable outcomes in Non-Secretory and Secretory Multiple myeloma after autologous stem cell transplantation Biol Blood Marrow Transplant. 2008 Oct;14(10):1134-40
17. Rotta M, Storer BE, Hari P, Storb RF, Maloney DG. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2008 Nov 17. [Epub ahead of print]
18. Brahmbhatt T, Hari P, Cinquegrani M, Kumar N, Komorowski R and Migrino RQ. Delayed enhancement on cardiac MRI in a patient with multiple myeloma without amyloidosis. Br J Radiol. 2008 Nov;81(971):e272-5.
19. Drobyski WR, Hari P, Keever-Taylor C et al. Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant. 2008 Sep 1. [Epub ahead of print]
20. Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P. Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. Cardiovasc Ultrasound. 2008 Aug 7;6:40
21. Smith SM, Van Besien K, Hari. P, Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug;14(8):904-12
22. Hari P, Carreras J, Zhang MJ et al. Allogeneic transplants in Follicular Lymphoma: Higher risk of disease progression after reduced intensity conditioning compared to myeloablative conditioning. Biol. Blood and Marrow Transplantation 2008 Feb;14(2):236-45
23. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007 Sep-Oct;57(5):301-18.
24. Sri Naveen Surapaneni, M.D., M.P.H, P. Hari, M.D., Josh Knox, P.A-C. Jack Daniel, R.N., and Kia Saeian, M.D. Suppressive Anti-HCV Therapy for Prevention of Donor to Recipient Transmission in Stem Cell Transplantation. Am J Gastroenterol 2007 Feb;102(2):449-51.
25. Hari P, Pasquini MC, Vesole DH.New questions about transplantation in multiple myeloma. Oncology (Williston Park); 2006 Sep;20(10):1230-42
26. Anagnostopoulos A, Hari P, Pérez WS, Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenstrom's Macroglobulinemia. Biol Blood Marrow Transplant 2006 Aug;12(8):845-54
27. Hari P, Pasquini M. Vesole DH Cure of multiple myeloma - more hype, less reality. Bone Marrow Transplant. 2006 Jan;37(1):1-18.
28. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR NF-{kappa}B as a target for the prevention of graft versus host disease: comparative efficacy of bortezomib and PS-1145.. Blood. 2005 Sep 20 Blood First Edition Paper, prepublished online September 20, 2005; DOI 10.1182/blood-2005-05-1820
29. Hari P, Drobyski, WR. Temporal Discordance of GVL and GVH reactitivy following DLI in Chronic Myeloid Leukemia. Biol Blood Marrow Transplant. 2004 Nov;10(11):743-7
30. Hari P, Vesole DH. Tandem Transplantation in Multiple Myeloma (Editorial) Oncology (Huntingt). 2003 Mar; 17(3):389-407.
31. Hari P, Prasad Chemiti GK, Lankipalli RS. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000 Dec 28;343(26):1968-9.
32. Hari P, Logan B, Drobyski WR. Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity? Biol Blood Marrow Transplant. 2004 Nov;10(11):743-7.
33. Hari P, Pasquini MC, Vesole DH. Cure of multiple myeloma -- more hype, less reality. Bone Marrow Transplant. 2006 Jan;37(1):1-18.
34. Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant. 2006 Aug;12(8):845-54.
35. Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K. Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. Am J Gastroenterol. 2007 Feb;102(2):449-51.
36. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant. 2008 Feb;14(2):236-45. PMCID: PMC2531158
37. Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P. Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. Cardiovasc Ultrasound. 2008 Aug 07;6:40. PMCID: PMC2525629
38. van Besien K, Hari P. Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood. 2008 Sep 15;112(6):2585-6; author reply 2586-7.
39. Kumar S, Pérez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2008 Oct;14(10):1134-1140. PMCID: PMC2634851
40. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. 2009 Apr 02;113(14):3383-91. PMCID: PMC2665904
41. Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009 Aug;23(8):1528-34. PMCID: PMC2726276
42. Migrino RQ, Christenson R, Szabo A, Bright M, Truran S, Hari P. Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. BMC Med Phys. 2009 May 05;9:5. PMCID: PMC2686669
43. Conway EJ, Wen J, Feng Y, Mo A, Huang WT, Keever-Taylor CA, Hari P, Vesole DH, Chang CC. Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry. Arch Pathol Lab Med. 2009 Oct;133(10):1594-9.
44. Harrington AM, Hari P, Kroft SH. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol. 2009 Jul;132(1):60-6.
45. Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, Gibson J, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A, McCarthy PL, Milone G, Omondi N, Reece DE, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee SJ, Rizzo JD, Mehta P. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010 Mar;16(3):395-402. PMCID: PMC2833344
46. Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P. Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. Br J Haematol. 2010 Aug;150(4):480-1.
47. Shidham VB, Hunt B, Jardeh SS, Barboi AC, Devata S, Hari P. Performing and processing FNA of anterior fat pad for amyloid. J Vis Exp. 2010 Oct 30(44). PMCID: PMC3185617
48. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011 Sep;17(9):1343-51. PMCID: PMC3150599
49. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug 18;118(7):1979-88. PMCID: PMC3158724
50. Devata S, Hari P, Markelova N, Li R, Komorowski R, Shidham VB. Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections. Cytojournal. 2011;8:11. PMCID: PMC3132327
51. Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ. Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012 May;18(5):690-7. PMCID: PMC3762249
52. Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2305-12. PMCID: PMC3233808
53. Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011 Nov 02;306(17):1874-83. PMCID: PMC3217787
54. Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant. 2012 Aug;18(8):1255-64. PMCID: PMC3376237
55. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770-81. PMCID: PMC3744390
56. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012 Aug 16;120(7):1367-79. PMCID: PMC5800543
57. Franco DA, Truran S, Burciu C, Gutterman DD, Maltagliati A, Weissig V, Hari P, Migrino RQ. Protective role of clusterin in preserving endothelial function in AL amyloidosis. Atherosclerosis. 2012 Nov;225(1):220-3. PMCID: PMC3478430
58. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN, Lymphoma Working Committee of the CIBMTR. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15;120(20):4256-62. PMCID: PMC3501720
59. Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? Bone Marrow Transplant. 2013 Nov;48(12):1489-96.
60. Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T, Martin PJ, Storb R, Maloney DG, Storer B, Flowers ME. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant. 2013 Jun;19(6):949-57. PMCID: PMC3846289
61. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013 Apr 20;31(12):1530-8. PMCID: PMC3625710
62. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013 May;19(5):746-53. PMCID: PMC3650915
63. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31. PMCID: PMC3640440
64. Hari PN, McCarthy PL. Multiple myeloma: future directions in autologous transplantation and novel agents. Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S20-5.
65. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May;19(5):760-6. PMCID: PMC3816739
66. Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013 Feb;19(2):173-9. PMCID: PMC3553321
67. Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013 Nov;19(11):1615-24. PMCID: PMC3952066
68. Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013 Sep 01;31(25):3100-9. PMCID: PMC3753702
69. Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. Br J Haematol. 2013 Sep;162(5):648-56. PMCID: PMC3766698
70. Hari P, DeFor TE, Vesole DH, Bredeson CN, Burns LJ. Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Sep;19(9):1361-7.
71. Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013 Sep;19(9):1368-73.
72. Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM. Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant. 2013 Sep;19(9):1340-7. PMCID: PMC3755028
73. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97. PMCID: PMC3886623
74. Migrino RQ, Harmann L, Christenson R, Hari P. Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study. Heart Vessels. 2014 Nov;29(6):793-800. PMCID: PMC3992190
75. Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, Montoto S, Hari PN. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant. 2013 Dec;19(12):1740-4. PMCID: PMC3906436
76. Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Hsu KC. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. Biol Blood Marrow Transplant. 2013 Dec;19(12):1661-9. PMCID: PMC3914636
77. Freytes CO, Vesole DH, LeRademacher J, Zhong X, Gale RP, Kyle RA, Reece DE, Gibson J, Schouten HC, McCarthy PL, Lonial S, Krishnan AY, Dispenzieri A, Hari PN. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant. 2014 Mar;49(3):416-21. PMCID: PMC3947725
78. Truran S, Weissig V, Ramirez-Alvarado M, Franco DA, Burciu C, Georges J, Murarka S, Okoth WA, Schwab S, Hari P, Migrino RQ. Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury. J Liposome Res. 2014 Mar;24(1):69-73. PMCID: PMC3925072
79. Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. PMCID: PMC3961011
80. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014 Feb 01;32(4):273-81. PMCID: PMC3897255
81. Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014 Sep;99(9):1479-85. PMCID: PMC4562537
82. Michaelis LC, Hamadani M, Hari PN. Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. Expert Rev Hematol. 2014 Jun;7(3):321-4.
83. Kanate AS, Pasquini MC, Hari PN, Hamadani M. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells. 2014 Apr 26;6(2):69-81. PMCID: PMC3999783
84. Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Aug;20(8):1183-9. PMCID: PMC5036168
85. Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug;166(3):401-9.
86. Guddati AK, Kumar G, Ahmed S, Ali M, Kumar N, Hari P, Venu N. Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. Int J Hematol. 2014 Jun;99(6):758-65.
87. Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transplant. 2014 Dec;20(12):1926-31.
88. Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica. 2014 Oct;99(10):1624-31. PMCID: PMC4181260
89. Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA, Freytes CO, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney DG, Hari PN. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014 Nov;49(11):1360-5. PMCID: PMC4221526
90. Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P. Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803. PMCID: PMC4194262
91. Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. PMCID: PMC4194275
92. Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 2015 Jul;50(7):914-7.
93. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015 Jul;50(7):947-53. PMCID: PMC4490016
94. Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Jul;21(7):1155-66.
95. Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. Bone Marrow Transplant. 2015 Apr;50(4):610-2.
96. Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015 Apr;21(4):738-45. PMCID: PMC4359647
97. Costa LJ, Huang JX, Hari PN. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant. 2015 Apr;21(4):701-6. PMCID: PMC4361014
98. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014 Dec;15(13):1503-1512.
99. Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015 Feb;21(2):335-41. PMCID: PMC4297511
100. Karmali R, Dalovisio A, Borgia JA, Venugopal P, Kim BW, Grant-Szymanski K, Hari P, Lazarus H. All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. Blood Rev. 2015 Mar;29(2):71-80.
101. Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN. Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. Bone Marrow Transplant. 2015 Mar;50(3):449-51.
102. Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Biol Blood Marrow Transplant. 2015 Dec;21(12):2100-2105.
103. Cornell RF, Hari P, Drobyski WR. Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. Biol Blood Marrow Transplant. 2015 Dec;21(12):2061-2068. PMCID: PMC4639405
104. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec;50(12):1513-8. PMCID: PMC4548821
105. Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A. Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. Am J Hematol. 2015 Nov;90(11):E212-3. PMCID: PMC4618044
106. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. Biol Blood Marrow Transplant. 2015 Dec;21(12):2091-2099. PMCID: PMC4639453
107. Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015 Oct 15;121(20):3709-16. PMCID: PMC4592381
108. Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant. 2016 Jan;51(1):2-12.
109. Abidi MZ, D'Souza A, Kuppalli K, Ledeboer N, Hari P. CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure. Diagn Microbiol Infect Dis. 2015 Sep;83(1):46-8.
110. Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016 Jan;51(1):58-66. PMCID: PMC4703480
111. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. PMCID: PMC4757494
112. Epperla N, Fenske TS, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World J Transplant. 2015 Sep 24;5(3):81-8. PMCID: PMC4580930
113. Hamadani M, Balasubramanian S, Hari PN. Ibrutinib in Refractory Classic Hodgkin's Lymphoma. N Engl J Med. 2015 Oct;373(14):1381-2.
114. D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10;33(32):3741-9. PMCID: PMC4737858
115. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):458-63. PMCID: PMC3370942
116. Hari P, Prasad CG, Lankipalli R. Mother-to-child HCV transmission. Lancet. 2001 Jan 13;357(9250):142; author reply 143.
117. Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cell myeloma. Br J Haematol. 2011 May;153(3):408-11.
118. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood. 2006 Jan 15;107(2):827-34. PMCID: PMC1895627
119. Hari P, Pasquini MC, Vesole DH. New questions about transplantation in multiple myeloma. Oncology (Williston Park). 2006 Sep;20(10):1230-42; discussion 1242, 1244, 1249-50.
120. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May;15(5):554-63. PMCID: PMC3120935
121. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007 Sep-Oct;57(5):301-18.
122. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug;14(8):904-12. PMCID: PMC3353768
123. Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol. 2010 Nov 05;145(1):67-8. PMCID: PMC2974792
124. Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W. Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant. 2009 Jan;43(2):169-77.
125. Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W. Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant. 2009 Jan;43(2):169-77.
126. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006 Mar 02;354(9):980-2; discussion 980-2.
127. Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct;14(10):1118-1124. PMCID: PMC2584240
128. Brahmbhatt T, Hari P, Cinquegrani M, Kumar N, Komorowski R, Migrino RQ. Case report: Delayed enhancement on cardiac MRI in a patient with multiple myeloma without amyloidosis. Br J Radiol. 2008 Nov;81(971):e272-5.
129. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan;15(1):109-17. PMCID: PMC2929570
130. Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH. High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. Bone Marrow Transplant. 2012 Mar;47(3):399-403.
131. Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov;15(11):1455-64. PMCID: PMC2913553
132. Migrino RQ, Mareedu RK, Eastwood D, Bowers M, Harmann L, Hari P. Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr. 2009 Dec;22(12):1396-402. PMCID: PMC2787973
133. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010 Jan;16(1):35-45. PMCID: PMC2929576
134. Vogl DT, Wang T, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2011 Dec;17(12):1765-74. PMCID: PMC3175301
135. Migrino RQ, Hari P. Light chain amyloidosis circa 2010: six prognostic markers and one sobering reality. J Am Soc Echocardiogr. 2010 Jun;23(6):653-5.
136. Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia. 2010 Jul;24(7):1350-6. PMCID: PMC2957585
137. Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010 Jul 15;116(14):3469-76. PMCID: PMC3153958
138. Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Dec;17(12):1862-8. PMCID: PMC3716013
139. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant. 2012 Jul;18(7):1036-1043.e1. PMCID: PMC3894923
140. Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. Am J Clin Pathol. 2012 Mar;137(3):403-11.
141. Ringdén O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M, Kamble R, Freytes CO, Gale RP, Gibson J, Gupta V, Holmberg L, Lazarus H, McCarthy P, Meehan K, Schouten H, Milone GA, Lonial S, Hari PN. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant. 2012 Jun;47(6):831-7. PMCID: PMC3369112
142. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec;12(13):1195-203. PMCID: PMC3611089
143. Vasudev M, Bresnahan BA, Cohen EP, Hari PN, Hariharan S, Vasudev BS. Percussion hemoglobinuria - a novel term for hand trauma-induced mechanical hemolysis: a case report. J Med Case Rep. 2011 Oct 07;5:508. PMCID: PMC3213680
144. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149-57. PMCID: PMC4109061
145. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012 May;26(5):1091-7. PMCID: PMC3274611
146. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10;119(19):4375-82.
147. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol. 2012 Jul 10;30(20):2492-9. PMCID: PMC4874149
148. Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. PMCID: PMC5030817
149. Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A. Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2016 Feb;51(2):297-9. PMCID: PMC4956087
150. Zhu F, Heditke S, Kurtzberg J, Waters-Pick B, Hari P, Margolis DA, Keever-Taylor CA. Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products. Cytotherapy. 2015 Dec;17(12):1813-9.
151. Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW. Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. Biol Blood Marrow Transplant. 2015 Nov;21(11):1883-7. PMCID: PMC4604067
152. Costa LJ, Hari PN, Kumar SK. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma. 2016 12;57(12):2827-2832.
153. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone Marrow Transplant. 2016 12;51(12):1602-1604.
154. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 10;22(10):1893-1899. PMCID: PMC5090978
155. Gallo S, Woolfrey AE, Burroughs LM, Storer BE, Flowers ME, Hari P, Pulsipher MA, Heimfeld S, Kiem HP, Sandmaier BM, Storb R. Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? Bone Marrow Transplant. 2016 Dec;51(12):1573-1578. PMCID: PMC5143192
156. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M. Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. Bone Marrow Transplant. 2017 01;52(1):147-150.
157. Beksac M, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P. HLA polymorphism and risk of multiple myeloma. Leukemia. 2016 11;30(11):2260-2264. PMCID: PMC5134914
158. Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jan;52(1):59-65. PMCID: PMC5215562
159. Franco DA, Truran S, Weissig V, Guzman-Villanueva D, Karamanova N, Senapati S, Burciu C, Ramirez-Alvarado M, Blancas-Mejia LM, Lindsay S, Hari P, Migrino RQ. Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins. J Am Heart Assoc. 2016 06 13;5(6). PMCID: PMC4937272
160. Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 10;22(10):1773-1780.
161. Hari P. Resistant or Sensitive: Time Is of the Essence: Response to Malek et al. Biol Blood Marrow Transplant. 2016 10;22(10):1908.
162. D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P. Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. 2017 09;178(5):816-819. PMCID: PMC5154782
163. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016 09 10;34(26):3141-9. PMCID: PMC5012706
164. Krishnan A, Vij R, Keller J, Dhakal B, Hari P. Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. Am Soc Clin Oncol Educ Book. 2016;35:210-21.
165. Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant. 2016 08;22(8):1391-1396. PMCID: PMC5075527
166. Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. Clin Lymphoma Myeloma Leuk. 2016 07;16(7):379-86.
167. Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ. DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. Case Rep Med. 2016;2016:8503275. PMCID: PMC4749780
168. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05;101(5):634-43. PMCID: PMC5004373
169. D'Souza A, Huang J, Hari P. New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Apr;22(4):768-770. PMCID: PMC4801777
170. Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016 Apr;51(4):492-500.
171. Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant. 2016 Apr;51(4):617-8.
172. Abidi MZ, Ledeboer N, Banerjee A, Hari P. Morbidity and mortality attributable to Rothia bacteremia in neutropenic and nonneutropenic patients. Diagn Microbiol Infect Dis. 2016 May;85(1):116-20.
173. Abidi MZ, Ledeboer N, Banerjee A, Hari P. Mycobacterium mucogenicum bacteremia in immune-compromised patients, 2008-2013. Diagn Microbiol Infect Dis. 2016 Jun;85(2):182-5.
174. Al-Hujaily EM, Oldham RA, Hari P, Medin JA. Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci. 2016 Sep 08;17(9). PMCID: PMC5037783
175. Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Res. 2016;5. PMCID: PMC4995679
176. Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 12;16(12):672-678.
177. Guzman-Villanueva D, Migrino RQ, Truran S, Karamanova N, Franco DA, Burciu C, Senapati S, Nedelkov D, Hari P, Weissig V. PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction. J Liposome Res. 2018 Jun;28(2):97-105. PMCID: PMC5591079
178. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematol Oncol. 2017 Dec;35(4):528-535.
179. Zheng C, Dai R, Hari PN, Zhang MJ. Instrumental variable with competing risk model. Stat Med. 2017 04 15;36(8):1240-1255. PMCID: PMC5479873
180. Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017 07 01;23(13):3307-3315. PMCID: PMC5496796
181. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. PMCID: PMC5346183
182. Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P. Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. Case Rep Hematol. 2016;2016:2389038. PMCID: PMC5097796
183. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant. 2017 01;23(1):60-66. PMCID: PMC5182098
184. Hari P, Raj RV, Olteanu H. Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. N Engl J Med. 2016 Oct 13;375(15):1501-1502.
185. Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P. Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jun;23(6):952-957.
186. Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. Biol Blood Marrow Transplant. 2017 Jul;23(7):1193-1202.
187. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 05;17(5):305-311.e2.
188. Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr Med Res Opin. 2017 06;33(6):1017-1031.
189. Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2017 May;23(5):853-856. PMCID: PMC5410937
190. Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clin Lymphoma Myeloma Leuk. 2017 03;17(3):165-172.
191. Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leuk Lymphoma. 2017 08;58(8):1872-1879.
192. Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017 08;178(4):571-582. PMCID: PMC5574012
193. Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer. 2017 Aug 15;123(16):3141-3149. PMCID: PMC5544566
194. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 07 13;130(2):221-228. PMCID: PMC5510790
195. Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 2017 12;31(12):2630-2641. PMCID: PMC5729352
196. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302.
197. Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P. Marizomib for central nervous system-multiple myeloma. Br J Haematol. 2017 04;177(2):221-225.
198. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol. 2017 Oct;92(10):E610-E611.
199. Eskandari F, Rowan DJ, Hari P, Kapke J, Schneidewend R, E Hagen C, Oshima K. Liver biopsy findings in patients with hematopoietic cell transplantation. Hum Pathol. 2017 08;66:136-143.
200. D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. Leukemia. 2017 09;31(9):1998-2000. PMCID: PMC5587375
201. Hari P. Recent advances in understanding multiple myeloma. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):267-271.
202. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. Am J Hematol. 2017 Sep;92(9):E563-E565.
203. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017 11;31(11):2443-2448.
204. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 07;17(7):408-414.
205. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov;23(11):1955-1960.
206. Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Br J Haematol. 2017 12;179(5):781-789.
207. Gajewski JL, McClellan MB, Majhail NS, Hari PN, Bredeson CN, Maziarz RT, LeMaistre CF, Lill MC, Farnia SH, Komanduri KV, Boo MJ. Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. Biol Blood Marrow Transplant. 2018 01;24(1):4-12.
208. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017 Dec;52(12):1616-1622. PMCID: PMC5859934
209. Hari P, Romanus D, Henk HJ, Becker LK, Noga SJ, Morrison VA. Factors associated with second-line triplet therapy in routine care in relapsed/refractory multiple myeloma. J Clin Pharm Ther. 2018 Feb;43(1):45-51.
210. Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A. Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):105-111.
211. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep;4(9):e431-e442. PMCID: PMC5718627
212. Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 05;24(5):983-988.
213. Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, Anderton K, Dixon P, Giralt SA. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2018 07;24(7):1379-1385.
214. Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clin Lymphoma Myeloma Leuk. 2018 02;18(2):152-160.
215. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft--host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 04;103(4):717-727. PMCID: PMC5865423
216. Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 05;24(5):895-908.
217. Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01;4(3):343-350. PMCID: PMC5885822
218. Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid. 2018 Mar;25(1):1-7.
219. Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018 03;20(3):394-406.
220. Hari P. Chemo-Mobilization in Myeloma-Diminishing Returns in the Era of Novel Agent Induction? Biol Blood Marrow Transplant. 2018 02;24(2):203-204.
221. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia. 2018 04;32(4):986-995. PMCID: PMC5871538
222. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biol Blood Marrow Transplant. 2018 03;24(3):478-485. PMCID: PMC5826888
223. Hari P, Romanus D, Luptakova K, Blazer M, Yong C, Raju A, Farrelly E, Labotka R, Morrison VA. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. J Geriatr Oncol. 2018 03;9(2):138-144.
224. Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH. Final outcomes of escalated melphalan 280 mg/m with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 2019 02;54(2):293-299.
225. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018 May 24;18(1):593. PMCID: PMC5968588
226. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 08;24(8):1610-1614.
227. Hari P, Lin HM, Zhu Y, Berg D, Richardson PG, Moreau P. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. J Med Econ. 2018 Aug;21(8):793-798.
228. Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH, Hari P, Padmanabhan A. Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol. 2018 May;5(5):e220-e231. PMCID: PMC6437775
229. D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials Commun. 2017 Dec;8:33-38. PMCID: PMC5898504
230. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 08;24(8):1664-1670.
231. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 09;53(9):1210-1213.
232. Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K. Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. Acta Haematol. 2018;139(3):171-175. PMCID: PMC6388419
233. Garderet L, Laubach JP, Stoppa AM, Hari P, Cavo M, Ludwig H, Mateos MV, Luptakova K, Lin J, Yung G, van de Velde H, Berg D, Moreau P, Richardson PG. Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia. 2018 09;32(9):2032-2036. PMCID: PMC6127091
234. Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E. Incidence and survival of therapy related myeloid neoplasm in United States. Leuk Res. 2018 08;71:95-99.
235. Wright NL, Flynn KE, Brazauskas R, Hari P, D'Souza A. Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease. Amyloid. 2018 Jun;25(2):129-134.
236. Costa LJ, Godby KN, Chhabra S, Cornell RF, Hari P, Bhatia S. Second primary malignancy after multiple myeloma-population trends and cause-specific mortality. Br J Haematol. 2018 08;182(4):513-520.
237. Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica. 2019 Feb;104(2):380-391. PMCID: PMC6355483
238. Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 01;25(1):e33-e38.
239. Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biol Blood Marrow Transplant. 2019 02;25(2):335-342. PMCID: PMC6339830
240. Badar T, D'Souza A, Hari P. Recent advances in understanding and treating immunoglobulin light chain amyloidosis. F1000Res. 2018;7. PMCID: PMC6117860
241. Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant. 2018 12;24(12):2443-2449. PMCID: PMC6293469
242. Dhakal B, Szabo A, Hari P. Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma-Reply. JAMA Oncol. 2018 11 01;4(11):1618.
243. Levin A, Hari P, Dhakal B. Novel biomarkers in multiple myeloma. Transl Res. 2018 11;201:49-59.
244. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica. 2019 Apr;104(4):844-854. PMCID: PMC6442962
245. Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biol Blood Marrow Transplant. 2019 04;25(4):699-711. PMCID: PMC6453753
246. Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahi PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wirk BM, Auletta J, Lindemans C, Riches M. Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. Bone Marrow Transplant. 2019 Aug;54(8):1354-1360.
247. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia. 2019 07;33(7):1736-1746. PMCID: PMC6755968
248. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 04;25(4):827-833.
249. Aljitawi OS, Hari P. Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma. Int J Hematol Oncol. 2016 May;5(1):5-10. PMCID: PMC6171969
250. Vazirabad I, Chhabra S, Nytes J, Mehra V, Narra RK, Szabo A, Jerkins JH, Dhakal B, Hari P, Anderson MW. Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. Biol Blood Marrow Transplant. 2019 05;25(5):921-931.
251. Hari P, Blazer M, Raju A, Farrelly E, Labotka R, Skacel T, Romanus D. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. Expert Rev Hematol. 2019 Jan;12(1):71-79.
252. Patel G, Hari P, Szabo A, Rein L, Kreuziger LB, Chhabra S, Dhakal B, D'Souza A. Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):10-14.
253. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019 Jul;25(7):1456-1464.
254. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266-2275. PMCID: PMC6820050
255. Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma. 2019 Oct;60(10):2558-2562.
256. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar;6(3):e132-e143. PMCID: PMC6503965
257. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019 06;25(6):1099-1106. PMCID: PMC6559839
258. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497.
259. Shah NN, Maatman T, Hari P, Johnson B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019;9:146. PMCID: PMC6423158
260. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 Jul 03;2(7):e196476.
261. Hari P, Paba-Prada CE, Voorhees PM, Frye J, Chang YL, Moreau P, Zonder J, Boccia R, Shain KH. Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Leuk Res. 2019 Aug;83:106172. PMCID: PMC6871647
262. Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S. Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. Haematologica. 2019 Jun 20.
263. Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P. Germline Risk Contribution to Genomic Instability in Multiple Myeloma. Front Genet. 2019;10:424. PMCID: PMC6518313
264. Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale GA, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biol Blood Marrow Transplant. 2019 May 06.
265. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biol Blood Marrow Transplant. 2019 Apr 17.
266. Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A. When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):e251-e258.
267. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694.
268. Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct;21(5):e13145.
269. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 04;25(4):683-688. PMCID: PMC6453717
270. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 Mar 01;37(7):589-597. PMCID: PMC6553842
271. Lazarus HM, Hamadani M, Hari PN. Autologous hematopoietic cell transplantation DeVita, Hellman, and Rosenberg's Cancer: Principles &amp; Practice of Oncology. 16 November 2018:2008-2019.
272. Hamadani M, Hari PN. Indications and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults Hematology: Basic Principles and Practice. 15 August 2017:1596-1607.
273. Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma [version 1; referees: 4 approved] F1000Research. 2016;5.
274. Lazarus HM, Hamadani M, Hari PN. Autologous stem cell transplantation DeVita, Hellman, and Rosenberg's Cancer: Principles &amp; Practice of Oncology: Tenth Edition. 7 January 2015.
275. Randhawa J, Singh V, Hari P. Allogeneic hematopoietic cell transplantation in multiple myeloma Cancer Consult: Expertise for Clinical Practice. June 20, 2014:381-387.
276. Hirudayaraj P, Hari PN. A poetic diagnosis: An interesting case of peripheral neuropathy Wisconsin Medical Journal. December 2009;108(9):476-477.
277. Surapaneni SN, Hari P, Saeian K. Response to Dr. Dai et al. [4] American Journal of Gastroenterology. October 2007;102(10):2351-2352.
278. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab [21] New England Journal of Medicine. 2 March 2006;354(9):981-982.
279. Rees JH. A pain in the back. N Engl J Med. 2001 Feb 08;344(6):456; author reply 456-7.
280. Semprini AE, Savasi V, Hollander L, Tanzi E. Mother-to-child HCV transmission. Lancet. 2001 Jan 13;357(9250):141; author reply 143.
281. Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P. Oprozomib in patients with newly diagnosed multiple myeloma Blood Cancer Journal. 1 September 2019;9(9).
282. Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale G, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematol Oncol Stem Cell Ther. 2019 Aug 20.
283. Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 07 29;9(8):56. PMCID: PMC6663939
284. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec;26(4):210-215.
285. D'Souza A, Hari P, Pasquini M, Jacobsen K, Flynn KE. Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. Amyloid. 2019;26(sup1):87-88.
286. Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S, KEYNOTE-183 Investigators. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e459-e469.
 
Books, Chapters, and Reviews
1. Hari P, and Horowitz MM. Outcomes of allogeneic transplantation in adults in Hoffman R et al (ed.s) Basic Principles and Practice of Hematology 5th edition Churchill Livingstone 2008.
2. Book Chapter : Marcelo C. Pasquini, Hari P, David H. Vesole. Transplante autólogo de células hematopoyéticas en mieloma múltiple. Multiple Myeloma (Spanish) Edited by Jorge Vela-Ojeda et al.
 
Editorials, Letters to Editor, Other
1. van Besien K, Hari P, Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood. 2008 Sep 15;112(6):2585-7.
2. Ozcan C, Wong S J, Hari P, Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006 Mar 2;354 (9):980-2;
3. Hari P, Chemiti GK, Joshi A. Brugada Syndrome Also Linked to Sudden Cardiac Death. Postgrad Med. Letter 2001 Feb; 109(2):18.
4. Hari P, Chemiti G, Lankipalli R. Minimum Intensity Anticoagulation Therapy as Primary Prevention Strategy. Arch Intern Med. 2001 Apr 9; 161(7): 1015-6.
5. Hari P, Joshi A, Chemiti GK. A Pain in the Back (Comment). N. Engl J Med. 2001 Feb 8;344(6): 456; discussion 456-7.
6. Hari P, Gopal C, Lankipalli R. Mother-to-Child HCV Transmission, Lancet 2001 Jan 13; 357 (9250): 142; discussion 143.
7. Hari P, Prasad Chemiti GK, Lankipalli RS. High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism. N. Engl Journal of Medicine. 2000 Dec. 28;p 343(26):1968-9.
 
Abstracts
1. Shaji Kumar, Ian W Flinn, Stephen J. Noga, P Hari et al. Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. 50th Annual Meeting American Society of Hematology December 2008 San Francisco
2. Cesar O Freytes, Jeanette Carreras & P Hari, Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL). 50th Annual Meeting American Society of Hematology December 2008 San Francisco
3. P Hari et al. Similar Outcomes among African-Americans (AA) and Whites after Autologous Hematopoietic-Cell Transplantation (Auto HCT) for Multiple Myeloma (MM). 50th Annual Meeting American Society of Hematology December 2008 San Francisco
4. Marcello Rotta, Barry Storer, P Hari et al. Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.50th Annual Meeting American Society of Hematology December 2008 San Francisco
5. Cheryl Cameron, Jeffrey Woodliff, Laura McOlash, P Hari et al. Use of a Potassium Channel Blocker to Inhibit Effector-Memory T Cells Isolated from Recipients of Allogeneic BMSCT. 50th Annual Meeting American Society of Hematology December 2008 San Francisco
6. Meral Beksac , Martin Maiers, P Hari, HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM). 50th Annual Meeting American Society of Hematology December 2008 San Francisco
7. Donna E. Reece, David H. Vesole, Smriti, .P Hari, Outcome of Patients with IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplants: A Retrospective CIBMTR Study. 50th Annual Meeting American Society of Hematology December 2008 San Francisco
8. Dan T. Vogl, Waleska S. Peréz, P Hari, Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) for Multiple Myeloma (MM): An Analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR). 50th Annual Meeting American Society of Hematology December 2008 San Francisco
9. Bright M, Hari P, Truran S, Wang J, Gutterman D, Migrino RQ. Serum protein carbonyl level is higher in AL amyloidosis patients versus healthy controls- evidence of systemic oxidative stress. Heart Failure Society of America 2008 Annual Scientific Meeting.
10. Migrino RQ, Pajewski N, Bright M, Malmsten C, Harmann L, Hari P, Echocardiographic predictors of 1-year mortality in light chain AL amyloidosis. Accepted for Heart Failure Society of America 2008 Annual Scientific Meeting.
11. Migrino RQ, Harmann L, Woods T, Bright M, and Hari P, Dyssynchrony in regional left ventricular systolic function in light chain amyloidosis: assessment using novel 4D echocardiography. Accepted for Heart Failure Society of America 2008 Annual Scientific Meeting.
12. Migrino RQ, Bright M, Hari P, Wang J, Kalyanaraman B, Gutterman D, Connors L and Phillips S. Endothelial dysfunction in human arterioles following exposure to primary amyloid light chain is improved by mitochondria-targeted antioxidant. Abstract 2008 American College of Cardiology Scientific Sessions, Chicago IL.
13. Migrino RQ, Phillips SA, Bright M, Wang J, Pajewski N, Prost R, Hari P, Adverse functional significance of delayed enhancement on cardiac MRI in primary systemic amyloidosis. Abstract 2008 Society for Cardiovascular Magnetic Resonance Scientific Session, Los Angeles CA.
14. Migrino RQ, Bright M, Hari P, Nguyen-Liu V, Connors L, Kalyanaraman B and Phillips S. Primary amyloidosis light chains impair endothelium-dependent vasodilation in human arterioles. Circulation 2007; 116:II-359.
15. Current Staging Systems Are Inadequate Predictors of Treatment Failure after Autologous Hematopoietic Stem Cell Transplants (AuHCT) in Multiple Myeloma (MM). Hari P, Waleska Pérez, Mei-Jie Zhang, Christopher Bredeson, Gustavo Milone, Donna Reece, Vivek Roy, David Vesole. American Society of Hematology Annual Meeting, December 2007
16. Comparable Outcomes in Secretory (SM) Versus Non-Secretory (NSM) Multiple Myeloma (MM) with Autologous Hematopoietic Stem Cell Transplantation (AuHCT). Shaji Kumar, Waleska S. Pérez, Mei-Jie Zhang, Christopher N. Bredeson, Martha Q. Lacy, Gustavo Milone, Donna Reece, David H. Vesole, Hari P, American Society of Hematology Annual Meeting December 2007
17. Pre-Transplant Rituximab Therapy Is Associated with Improved Progression-Free and Overall Survival in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma (DLBCL). Session Type: Oral Session. Timothy S. Fenske, P. Hari, Jeanette Carreras, Mei-Jie Zhang, Rammurti Kamble, J. Douglas Rizzo, Koen van Besien, Hillard M. Lazarus, Julie M. Vose American Society of Hematology Annual Meeting December 2007
18. Michael W. Schuster, J. Mehta, E.K. Waller, R.M. Rifkin, I. Micallef, D. Hurd, S. Parekh, P. Hari, B.S. Skikne, T.C. Shea, D.A. Frei-Lahr, R. Abonour, C.O. Freytes, L. Pineiro, Y.C. Halvorsen, E.J. Anaissie. A Randomized Placebo Controlled Phase II Trial of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative Therapy and Autologous Hematopoietic Stem Cell Transplant (AHSCT). American Society of Hematology Annual Meeting December 2007
19. Marcello Rotta, Barry Storer, Firoozeh Sahebi, Judith A. Shizuru, Bruno Benedetto, Thoralf Lange, Peter A. McSweeney, Michael A. Pulsipher, P. Hari, Richard T. Maziarz, Edward D. Agura, Thomas Chauncey, Frederick R. Appelbaum, Mohamed L. Sorror, William Bensinger, Brenda M. Sandmaier, Rainer F. Storb, David G. Maloney Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM). American Society of Hematology Annual Meeting December 2007
20. Migrino RQ, Nguyen-Liu V, Wang J, Pratt P, Pritchard K, Hari P,. Delayed enhancement is associated with more advanced diastolic dysfunction in primary systemic amyloidosis. J Cardiovascul Mag Res 2007; 9(2):321-322.
21. Migrino RQ, Pritchard K, Wang J, Nguyen-Liu V, Pratt P, Hari P,. Elevated pro-inflammatory HDL in primary amyloidosis: potential role of oxidative stress in cardiac injury. J Am Coll Cardiol 2007; 49(9A): 46A.
22. Marcel P. Devetten, P. Hari, Jeanette Carerras, Brent R. Logan, Koen van Besien, Julie M. Vose, Hillard M. Lazarus, and Paolo Anderlini Unrelated Donor Nonmyeloablative/Reduced Intensity (NST/RIC) Hematopoietic Stem Cell Transplantation (HCT) for Patients with Relapsed and Refractory Hodgkin's Lymphoma (HL). Blood 108: 601.
23. Asad Bashey, Waleska S. Perez, Mei-Jie Zhang, David H. Vesole, Donna E. Reece, Hartmut Goldschmidt, and P. Hari, Outcomes Following Syngeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Matched Comparison to Autologous Transplantation. Blood 108: 50.
24. Brandon Hayes-Lattin, Jeanette Carreras, Mei-Jie Zhang, Koen van Besien, Julie M. Vose, Hillard M. Lazarus, J. Douglas Rizzo, and P. Hari,. Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity. Blood 108: 3021.
25. Sonali M. Smith, Koen van Besien, Jeanette Carreras, Julie M. Vose, Hillard M. Lazarus, and P. Hari, Clinical Outcome of a Second Autologous Hematopoietic Stem Cell Transplant (HCT) for Non-Hodgkin (NHL) and Hodgkin Lymphoma (HL) Relapsing after a First Autotransplant. Blood 108: 3048.
26. P. Anderlini, P. Hari, J. Carreras, B. Logan, K. van Besien, J. Vose, H. Lazarus, M. Devetten on behalf of the Writing Committee, CIBMTR, Medical College of Wisconsin, Milwaukee, USA Unrelated donor non-myeloablative/reduced-intensity haematopoietic stem cell transplantation for patients with relapsed and refractory Hodgkin's Lymphoma Bone Marrow Transplant 39: S1-S55; O278
27. Hari P, Sanja Vodanovic-Jankovic, Paulette Jacobs, and Richard Komorowski, William R. Drobyski.Targeting NF-Kß for the Prevention of Graft Versus Host Disease.Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 3109
28. Hari P, Koen Van Besien, Jeanette Carreras, Mei-Jie Zhang, Julie Vose, Hillard Lazarus, Christopher Bredeson, Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 656.
29. Hari, P, Vasudev B, Vasudev M, A case of Percussion Hemoglobinuria, Presented at American Society of Nephrology Nov 8-11, 2005
30. B. Siddiqi, P. van Tuinen, RN. Rao, L. Novoa-Takara, VB. Shidham, C. Chitambar, P. Hari, B. Kampalath. MUM1/IRF4 Expression in Mantle Cell Lymphoma Correlates with Diffuse Morphology. United States and Canadian Academy of Pathology Annual Meeting 2004, Abstract 1136
31. B. Siddiqi, P. van Tuinen, VB. Shidham, RN. Rao, L. Novoa-Takara, CR. Chitambar, P. Hari, B. Kampalath. MUM1/IRF4 Expression in Background T-cells in Diffuse and Nodular Variants of Mantle Cell Lymphoma. United States and Canadian Academy of Pathology Annual Meeting 2004, Abstract 1137
32. B. Siddiqi, P. Hari, DH. Vesole, CC. Chang, L. Novoa-Takara, VB. Shidham, B. Kampalath. CD20 and CD117 Expression Correlates with Plasma Cell Morphology in Plasma Cell Myeloma. United States and Canadian Academy of Pathology Annual Meeting 2004, Abstract 1138
33. Hari P, Atrial Fibrillation (AF) as a Complication of Autologous Stem Cell Transplant (ASCT) with Higher Doses of Melphalan (MEL) in Multiple Myeloma (MM) Patients. Thumma S et al Blood (suppl.) Volume 102 issue 11; 2003.
34. Hari P, Thumma S. Phase I/II Trial of Dose Escalation of Melphalan (MEL) with Amifostine (AMI) Cytoprotection Supported by Autologous Hematopoietic Stem Cell Transplant (HSCT) in Multiple Myeloma (MM) Patients >65 Years. Et al Blood (Suppl) Volume 102 issue 11;2003.
35. Hari P, Venugopal P, Sivaraman S. Analysis of Time Sequence of CD20 Antigen Expression Changes on Tumor Cells Following Exposure to Cytokines. (ASH abstract) et al Blood (suppl) 98, 11 Nov 2001.
36. Hari P, Joshi A, Chemiti GK. Spontaneous Intraspinal Hemorrhage in Polycythemia Vera: Thrombosis Followed by Bleeding. Et al (ASH abstract) Blood (suppl) 98, 11 Nov 2001.
37. Hari P, Nathan N, Joshi A. Phlegmonous Bacterial Discitis in Myeloma (ASH abstract) Blood (suppl) 98, 11 Nov 2001.
38. Hari P, Nathan N, Joshi A. Primary Intradural Intramedullary Hodgkins Lymphoma et al (ASH abstract) Blood (suppl) 98, 11 Nov 2001
39. Hari P, Yunus F, Wooldridge JE, Venugopal P. Phase II Study of Rituximab in Combination with CHOP Chemotherapy and GMCSF (Leukine) in Patients with Previously Untreated Diffuse Large Cell Lymphoma (DLCL) and Mantel Cell Lymphoma (MCL) et al (ASH abstract) Blood (suppl) 98, 11 Nov 2001.
40. Hari P, N, Chapman C.S. Prevalence of Beta Thalassemia Among British Hindus in Leicester, British Journal of Hematology 1999; 105, Suppl 1, 80.
 

jenkins-FCD Prod-410 e9586552fe7f53c71f7923aa6e27aeabbd3c2473